- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 211/60
Total number of patents in this class: 602
10-year publication summary
|
42
|
51
|
58
|
41
|
49
|
32
|
40
|
27
|
41
|
31
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| ChemoCentryx, Inc. | 356 |
34 |
| Meiji Seika Pharma Co., Ltd. | 257 |
15 |
| Corsair Pharma, Inc. | 38 |
13 |
| Novartis AG | 10163 |
10 |
| Life Technologies Corporation | 3626 |
10 |
| Omeros Corporation | 305 |
10 |
| Biogen MA Inc. | 948 |
9 |
| Ube Corporation | 468 |
9 |
| Bristol-myers Squibb Company | 4756 |
7 |
| Kaneka Corporation | 4844 |
7 |
| Helsinn Healthcare SA | 224 |
7 |
| Xinfa Pharmaceutical Co., Ltd. | 23 |
7 |
| The Regents of the University of California | 20989 |
6 |
| Pfizer Inc. | 3433 |
6 |
| Takeda Pharmaceutical Company Limited | 2704 |
6 |
| Global Blood Therapeutics, Inc. | 165 |
6 |
| Bnh Research Co.,Ltd. | 10 |
6 |
| Araxes Pharma LLC | 90 |
5 |
| Rottapharm Biotech S.r.l. | 42 |
5 |
| West China Hospital, Sichuan University | 243 |
5 |
| Other owners | 419 |